MEMBER'S AREA
GET IN TOUCH
JOIN US!

Obituary

Dr Francis H Glorieux

by

It is with deep sorrow and immense respect that the International Society for Children’s Bone Health (ISCBH) honors the extraordinary life and legacy of Dr. Francis H. Glorieux.

Dr. Glorieux has transformed the care of thousands of children and families worldwide living with pediatric bone disorders. He held a truly special place in the hearts of his patients, who felt genuinely heard, respected, and empowered by him. He was driven by a strong conviction and sincere desire to improve their lives. He continued to support patients in need until the end of his life.

In 1972, Dr. Glorieux was instrumental in establishing the combined use of active vitamin D and oral inorganic phosphate supplementation as the standard therapeutic approach for X-linked hypophosphatemic rickets. In 1998, he and his colleagues demonstrated that intravenous bisphosphonate therapy produced substantial improvements in bone density, fracture rate, and pain in children with severe osteogenesis imperfecta, fundamentally changing the standard of care for this disorder. The protocols developed at Shriners Children’s Canada have been widely adopted internationally, and are now recognized as the standard of care, enhancing quality of life for children with bone fragility.

Dr. Glorieux has contributed to discoveries of several novel genetic forms of osteogenesis imperfecta fundamentally expanding the clinical and molecular understanding of the disease, shifting the paradigm from a disorder solely of type I collagen defects to a genetically and mechanistically heterogeneous group of diseases. Dr. Glorieux also pioneered work in pediatric bone histomorphometry and provided the first comprehensive set of normative data in healthy children and adolescents, supporting the use of bone histomorphometry as the gold standard for evaluating bone metabolism and pathology in the pediatric population.

Dr. Glorieux has mentored and inspired countless clinicians and researchers who now dedicate their lives to caring for children with bone diseases around the world. His enduring influence lives on in the global community he helped build—one rooted in excellence, collaboration, and an unwavering commitment to improving the lives of children with bone disorders. In 2024, the Canadian Osteogenesis Imperfecta Society inaugurated the Francis Glorieux Research Fellowship to support new investigators conducting research in the field of osteogenesis imperfecta.

In 1999, he was the first recipient of the Charles Slemenda Award, established by ISCBH in recognition of outstanding contributions to children’s bone research. This was just one of many awards and accolades Dr Glorieux received throughout his career.

Dr. Glorieux’s legacy is one of profound transformation—scientifically, through groundbreaking advances, and humanistically, through kindness and sincere respect he showed those he cared for and the community he built. Dr. Glorieux’s presence lives on in the gratitude, strength, and love of the families he so deeply touched, and in the dedication and compassion of the clinicians he mentored—his legacy enduring through all they continue to do in his memory.

 

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

At Kyowa Kirin, patients are at the center of everything we do. We are a global specialty pharmaceutical company dedicated to discovering and advancing innovative medicines for rare and hard-to-treat diseases where unmet need is greatest. Based in Japan with worldwide operations, we work across the continuum—from drug discovery to commercialization—guided by our commitment to patients and their families. Backed by more than 70 years of life sciences leadership, we focus on bone and mineral disorders, hemato-oncology, and rare diseases. Rooted in collaboration, we accelerate development through partnerships with industry, academia, patients, and healthcare providers. Learn more: KyowaKirin.com

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE
BridgeBio Logo

At BridgeBio, our mission is to turn beautiful science into meaningful medicines for the people who need it most. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE